Another CTA termed as preferentially expressed antigen in melanoma (PRAME) whose expression is primarily upregulated by DNA demethylation and its expression has been associated with favorable outcomes in leukemias including AML (52). This evidence concerns the gene PRAME and acute myeloid leukemia.